CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 2017; 35: 3330-3337.

Published: 17th May 2018

Authors: Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W et al.

Conclusion

The addition of erlotinib did not improve disease-free (11.4 months in both groups), or overall survival (24.5 months versus 26.5 months with gemcitabine alone) in this study that included 436 patients.

Pubmed Link

Your comments

0 Comments